Valcyte
Valcyte is an originator product from Cheplapharm Schweiz GmbH and is listed on the FOPH Specialities List. Swiss mandatory health insurance therefore reimburses it within the authorised indication. The public price ranges from CHF 1'018.20 to CHF 1'018.20 depending on the pack; the patient co-payment is 10 per cent plus the deductible.
Core data
- Authorisation holder
- Cheplapharm Schweiz GmbH
- ATC code
- J05AB14
- IT group
- 08.03 Mittel gegen Viren
- Active substances
- Valganciclovirum
- Preparation type
- Originator product
- On the SL since
- 01/11/2002
- Last price change
- 01/02/2026
- Co-payment
- 10%
Prices per pack
The ex-factory price is the authorisation holder's price; the public price adds the distribution share and VAT. Both are FOPH maximum prices: nothing above them may be charged.
| Dosage form | Pack size | Ex-factory price | Public price | Valid from | Cat. | GTIN |
|---|---|---|---|---|---|---|
| Filmtabl | 60 Stk | CHF 929.03 | CHF 1'018.20 | 01/11/2002 | A | 7680559050027 |
Limitation
No limitation is recorded on the SL for this preparation.
More preparations in this group
FAQ
Is Valcyte covered by Swiss health insurance?
Yes. Valcyte is on the FOPH Specialities List, so Swiss mandatory health insurance reimburses it within the authorised indication. You still pay the deductible and a co-payment of 10 per cent.
What does Valcyte cost in Switzerland?
The public price is the maximum price set by the FOPH and for Valcyte ranges from CHF 1'018.20 to CHF 1'018.20 per pack. The ex-factory price ranges from CHF 929.03 to CHF 929.03. Pharmacies may not charge more, but may charge less.
Market access
Do you need your product on the Specialities List?
Questions about SL listing, prices or limitations? Contact Swiss Reimbursement.
- Independent directory
- Official FOPH data
- Website in eight languages